Estimates Revisions Telix Pharmaceuticals Limited Nasdaq
Stocks
TLX
US87961M1053
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.79 USD | +2.34% |
|
+17.66% | +57.41% |
| 08-06 | ASX Biggest Gainers | MT |
| 07-24 | Telix Says Thyroid Cancer Therapy Candidate Shows Encouraging Disease Control, Acceptable Safety Profile in Real-World Data Review | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- TLX Stock
- TLX Stock
- Consensus Telix Pharmaceuticals Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
